Table 5.
Summary of breakeven analyses.
| Scenario | Description | Budget impact per patient (US$) | Change versus base case (absolute/%) | Reference |
|---|---|---|---|---|
| Base case | See Table 2 | −7886 | ||
| 1. Efficacy | NAVA: 22% | −7612 | −274/–3% | Hypothetical |
| PSV: 52% | ||||
| Absolute difference: 30% | ||||
| 2. Efficacy | NAVA: 32% | −4870 | −3017/–38% | Hypothetical |
| PSV: 52% | ||||
| Absolute difference: 20% | ||||
| 3. Efficacy | NAVA: 42% | −2127 | −5759/–73% | Hypothetical |
| PSV: 52% | ||||
| Absolute difference: 10% | ||||
| 4. Efficacy | NAVA: 49.5% | −71 | −8501/–108% | Hypothetical |
| PSV: 52% | ||||
| Absolute difference: 2.5% | ||||
| 5. Efficacy | NAVA: 52% | 615 | −8501/–108% | Hypothetical |
| PSV: 52% | ||||
| Absolute difference: 0% |
In addition to the base case, five scenarios were tested in order to define the required difference in proportion of asynchronous patients with asynchrony index at least 10% for breakeven, where the incremental cost of NAVA equals the economic gain from reducing asynchrony.
NAVA, Neurally Adjusted Ventilator Assist; PSV, pressure support ventilation.